Viewing Study NCT06108232


Ignite Creation Date: 2025-12-24 @ 9:30 PM
Ignite Modification Date: 2025-12-25 @ 7:15 PM
Study NCT ID: NCT06108232
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2023-10-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module